Keytruda® (pembrolizumab) – New indication
June 18, 2019 - Merck announced the FDA approval of Keytruda (pembrolizumab), for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.
Top